LIFECORE BIOMEDICAL, INC. Gains (Losses) on Restructuring of Debt
LIFECORE BIOMEDICAL, INC. (LFCR) reported Gains (Losses) on Restructuring of Debt of $0 for the 12-month period ending 2022-05-29, per its 10-K/A filed 2023-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnRestructuringOfDebt · last filed 2024-03-20
- LIFECORE BIOMEDICAL, INC. gains (losses) on restructuring of debt for the quarter ending 2022-05-29 was $0.00.
- LIFECORE BIOMEDICAL, INC. gains (losses) on restructuring of debt for the quarter ending 2022-02-27 was $0.00.
- LIFECORE BIOMEDICAL, INC. gains (losses) on restructuring of debt for the quarter ending 2021-05-30 was $0.00.
- LIFECORE BIOMEDICAL, INC. gains (losses) on restructuring of debt for the quarter ending 2021-02-28 was -$1.11M.
- LIFECORE BIOMEDICAL, INC. gains (losses) on restructuring of debt for fiscal 2022 was $0.00.
- LIFECORE BIOMEDICAL, INC. gains (losses) on restructuring of debt for fiscal 2021 was -$1.11M.
- LIFECORE BIOMEDICAL, INC. gains (losses) on restructuring of debt for fiscal 2020 was $0.00.
- LIFECORE BIOMEDICAL, INC. gains (losses) on restructuring of debt for fiscal 2019 was $0.00.
| Period end | Gains (Losses) on Restructuring of Debt 3 month | Gains (Losses) on Restructuring of Debt 6 month | Gains (Losses) on Restructuring of Debt 9 month | Gains (Losses) on Restructuring of Debt 12 month |
|---|---|---|---|---|
| 2022-05-29 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 10-K/A · filed 2023-03-16 | |
| 2022-02-27 | $0.00 10-Q · filed 2022-04-07 | $0.00 10-Q · filed 2022-04-07 | ||
| 2021-05-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$1.11M derived: sum of 2 quarters · filed 2024-03-20 | -$1.11M 10-K · filed 2024-03-20 | |
| 2021-02-28 | -$1.11M 10-Q · filed 2022-04-07 | -$1.11M 10-Q · filed 2022-04-07 | ||
| 2020-05-31 | $0.00 10-K/A · filed 2023-03-16 | |||
| 2019-05-26 | $0.00 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |